These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 24015417)

  • 1. [Picture in clinical hematology].
    Hatsuse M; Shimazaki C; Yumiba T
    Rinsho Ketsueki; 2013 Jan; 54(1):1. PubMed ID: 24015417
    [No Abstract]   [Full Text] [Related]  

  • 2. [Vocal cord paralysis secondary to vincristine].
    Nafil H; Tazi I; Mahmal L
    Rev Neurol (Paris); 2012 May; 168(5):464-5. PubMed ID: 22387202
    [No Abstract]   [Full Text] [Related]  

  • 3. Reversible posterior leukoencephalopathy syndrome following R-CHOP therapy for diffuse large B-cell lymphoma.
    Hosoi M; Yamamoto G; Imai Y; Kurokawa M
    Ann Hematol; 2010 Feb; 89(2):207-8. PubMed ID: 19582454
    [No Abstract]   [Full Text] [Related]  

  • 4. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
    Coiffier B; Lepage E; Briere J; Herbrecht R; Tilly H; Bouabdallah R; Morel P; Van Den Neste E; Salles G; Gaulard P; Reyes F; Lederlin P; Gisselbrecht C
    N Engl J Med; 2002 Jan; 346(4):235-42. PubMed ID: 11807147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma.
    Furman RR; Martin P; Ruan J; Cheung YK; Vose JM; LaCasce AS; Elstrom R; Coleman M; Leonard JP
    Cancer; 2010 Dec; 116(23):5432-9. PubMed ID: 20665890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic polymorphism at
    Bashash M; Connors JM; Gascoyne RD; Meissner B; Schuetz JM; Leach S; Slack GW; Berry BR; Hu H; Sehn LH; Brooks-Wilson AR; Spinelli JJ
    Haematologica; 2017 May; 102(5):e199-e202. PubMed ID: 28154089
    [No Abstract]   [Full Text] [Related]  

  • 7. Outcomes with R-CEOP for R-CHOP-ineligible patients with diffuse large B-cell lymphoma are highly dependent on cell of origin defined by Hans criteria.
    Rashidi A; Oak E; Carson KR; Wagner-Johnston ND; Kreisel F; Bartlett NL
    Leuk Lymphoma; 2016 May; 57(5):1191-3. PubMed ID: 26397936
    [No Abstract]   [Full Text] [Related]  

  • 8. Increased rituximab (R) doses eliminate increased risk and improve outcome of elderly male patients with aggressive CD20+ B-cell lymphomas: the SEXIE-R-CHOP-14 trial of the DSHNHL.
    Clin Adv Hematol Oncol; 2014 Aug; 12(8 Suppl 16):8-9. PubMed ID: 25768993
    [No Abstract]   [Full Text] [Related]  

  • 9. MYC gene rearrangement in diffuse large B-cell lymphoma does not confer a worse prognosis following dose-adjusted EPOCH-R.
    Lai C; Roschewski M; Melani C; Pittaluga S; Shovlin M; Steinberg SM; Dunleavy K; Pack S; Jaffe ES; Wilson WH
    Leuk Lymphoma; 2018 Feb; 59(2):505-508. PubMed ID: 28641474
    [No Abstract]   [Full Text] [Related]  

  • 10. [A case of neurotoxicity reduced with pregabalin in R-CHOP chemotherapy for diffuse large B-cell lymphoma].
    Nakashima T; Kiba T; Ogawa Y; Kimura A; Kido M; Okikawa Y; Ito T; Saito A; Hosokawa A; Shintani H; Okada Y; Taniguchi T; Taniyama K; Kozawa K; Niimi H
    Gan To Kagaku Ryoho; 2012 May; 39(5):809-12. PubMed ID: 22584337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CHOP chemotherapy as standard therapy for treatment of patients with diffuse histiocytic lymphoma.
    Fisher RI
    Important Adv Oncol; 1990; ():217-25. PubMed ID: 2182520
    [No Abstract]   [Full Text] [Related]  

  • 12. CHOP plus rituximab--balancing facts and opinion.
    Cheson BD
    N Engl J Med; 2002 Jan; 346(4):280-2. PubMed ID: 11807154
    [No Abstract]   [Full Text] [Related]  

  • 13. DLBCL developed into fatal liver failure during rituximab-containing chemotherapy.
    Shimazu Y; Nohgawa M
    J Clin Exp Hematop; 2019; 59(2):93-95. PubMed ID: 31257349
    [No Abstract]   [Full Text] [Related]  

  • 14. The clinician's decision of whether CHOP chemotherapy should be standard therapy for treatment of patients with diffuse histiocytic lymphoma.
    Connors JM
    Important Adv Oncol; 1990; ():227-33. PubMed ID: 2182521
    [No Abstract]   [Full Text] [Related]  

  • 15. [Evaluation of the impact of R-CHOP chemotherapy on efficacy, safety and prognosis in newly diagnosed diffuse large B-cell lymphoma patients and its prognostic impact: a multicenter retrospective study with long term follow-up].
    Cheng ZX; Zou SH; Li F; Li JM; Wang JM; Chen FY; Cao JN; Wang C; Wei Z; Cheng YF
    Zhonghua Xue Ye Xue Za Zhi; 2012 Apr; 33(4):257-60. PubMed ID: 22781712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymphomatous pericardial effusion positive for Mycobacterium tuberculosis by PCR analysis.
    Michelis FV; Petrogiannopoulos CL; Papamichael KX; Kostakos ND; Kiagia EZ; Deliousis A; Zacharof AK
    Int J Infect Dis; 2008 Sep; 12(5):564-5. PubMed ID: 18406651
    [No Abstract]   [Full Text] [Related]  

  • 17. Impact of rituximab on treatment outcomes of patients with diffuse large b-cell lymphoma: a population-based analysis.
    Lee L; Crump M; Khor S; Hoch JS; Luo J; Bremner K; Krahn M; Hodgson DC
    Br J Haematol; 2012 Aug; 158(4):481-8. PubMed ID: 22671571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma.
    Gordon LI; Harrington D; Andersen J; Colgan J; Glick J; Neiman R; Mann R; Resnick GD; Barcos M; Gottlieb A
    N Engl J Med; 1992 Nov; 327(19):1342-9. PubMed ID: 1383819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular analysis of a CD19-negative diffuse large B-cell lymphoma.
    Delage L; Manzoni D; Quinquenet C; Fontaine J; Maarek A; Chabane K; Mosnier I; Hayette S; Callet-Bauchu E; Grange B; Plesa A; Sujobert P
    Haematologica; 2019 Mar; 104(3):e114-e116. PubMed ID: 30545922
    [No Abstract]   [Full Text] [Related]  

  • 20. Phase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T-cell lymphoma.
    Oki Y; Younes A; Copeland A; Hagemeister F; Fayad LE; McLaughlin P; Shah J; Fowler N; Romaguera J; Kwak LW; Pro B
    Br J Haematol; 2013 Jul; 162(1):138-41. PubMed ID: 23590726
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.